Successful Treatment of Severe Pyoderma Gangrenosum and Ulcerative Colitis With Upadacitinib.
Pyoderma gangrenosum (PG) is a rare inflammatory and ulcerative skin disorder that is often associated with an underlying systemic disease, including inflammatory bowel disease. Many treatments used to treat inflammatory bowel disease are also used for the treatment of PG, including systemic therapi...
| Publicado en: | ACG Case Reports Journal Vol. 11; no. 10; pp. 1 - 5 |
|---|---|
| Autores principales: | , , , |
| Formato: | case study diagnostic images pictorial tables/charts Journal Article |
| Publicado: |
American College of Gastroenterology
Oct2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| Sumario: | Pyoderma gangrenosum (PG) is a rare inflammatory and ulcerative skin disorder that is often associated with an underlying systemic disease, including inflammatory bowel disease. Many treatments used to treat inflammatory bowel disease are also used for the treatment of PG, including systemic therapies, immunomodulators, and tumor necrosis factor-a inhibitors; however, their efficacy in PG is limited. Novel treatments of PG are needed. We report the case of a 62-year-old woman with steroid-refractory PG and concomitant ulcerative colitis successfully treated for both conditions with upadacitinib, a selective Janus kinase inhibitor. |
|---|